Chronic lymphocytic leukaemia

@article{Hallek2018ChronicLL,
  title={Chronic lymphocytic leukaemia},
  author={Michael Hallek and Tait D. Shanafelt and Barbara F. Eichhorst},
  journal={The Lancet},
  year={2018},
  volume={391},
  pages={1524-1537}
}
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For… Expand
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
  • Y. Kikushige
  • Medicine
  • Journal of clinical and experimental hematopathology : JCEH
  • 2020
TLDR
The development of therapeutic approaches, especially that of molecular target therapies against CLL, has markedly improved the standard of care for CLL and the development of novel therapeutic strategies are reviewed. Expand
Recent advances in chronic lymphocytic leukemia therapy
  • J. Uhm
  • Medicine
  • Blood research
  • 2020
TLDR
This review will focus on the risk stratification and the management of CLL in the era of novel small molecules. Expand
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
TLDR
It is believed that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine. Expand
A Study of Genomic Instability in Chronic Lymphocytic Leukaemia (CLL)
TLDR
Genotyping data shows that many genes could be affected, involving signal transduction and immune response pathways that may participate in B cell development and CLL pathogenesis affected novel cells, supporting the possibility that oncogenes may initiate CLL carcinogenesis prior to TP53 mutation and chromosomal instability. Expand
Precision Medicine Management of Chronic Lymphocytic Leukemia
TLDR
Overall, precision medicine is now a mainstay in the management and treatment stratification of CLL, and the identification of novel predictive biomarkers will allow further improvements in the treatment tailoring of this leukemia. Expand
[Chronic lymphocytic leukemia].
TLDR
Therapy is only required if there are pronounced symptoms or changes in the blood count, such as a relevant drop in hemoglobin and/or platelets, and the prognosis strongly depends on the individual molecular and cytogenetic risk factors. Expand
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
TLDR
The development and latest clinical data that have led to the expanded approval of venetoclax with rituximab in relapsed/refractory CLL/SLL are reviewed and ongoing and future clinical trials designed to evaluate the efficacy of venEToclax in previously untreated patients and in combination with inhibitors of B-cell receptor signaling pathway are discussed. Expand
Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia
TLDR
Treatment approaches for patients with CLL should be individualized and that there is still a role, albeit diminished, for CIT in the treatment of CLL, predominately in the front-line setting. Expand
Pathophysiology of chronic lymphocytic leukemia and human B1 cell development
  • Y. Kikushige
  • Biology, Medicine
  • International Journal of Hematology
  • 2019
TLDR
This review focuses on recent insights into CLL leukemogenesis, emphasizing the role of genetic lesions, and the multistep process initiating from very immature hematopoietic stem cells, and progress in the study of human B1 B cells, the putative normal counterparts of CLL cells. Expand
Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics
TLDR
This review focuses on biomarkers revealed by investigations of CLL molecular genetics and immunogenetics that may help optimizing therapy for individual patients, and that may allow one step forward in the precision medicine approach to CLL. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 139 REFERENCES
Viral infections and their management in patients with chronic lymphocytic leukemia
TLDR
A review of the available data on infection with or reactivation of viral diseases in patients with chronic lymphocytic leukemia and the degree and quality of immunosuppression is thus substantially different from that observed during the treatment of other indolent lymphomas and warrants special consideration. Expand
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.
TLDR
The currently available diagnostic and therapeutic tools and an integrated recommendation of how to manage CLL in 2013 are summarized and a strategy how the novel agents for CLL therapy into sequential treatment approaches in the near future is proposed. Expand
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
TLDR
Ofatumumab-based consolidation appears to be a well tolerated and effective consolidation strategy in patients with chronic lymphocytic leukaemia, which could improve survival. Expand
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
TLDR
Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population. Expand
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
TLDR
The activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytics lymphoma is assessed. Expand
Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation
TLDR
Early treatment of CLL with intermittent chlorambucil did not result in a survival advantage for patients with indolent stage I and II CLL at 5 years from randomization. Expand
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
TLDR
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. Expand
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia
TLDR
The choice between ibrutinib and idelalisib should be based on the patients' comorbidities and concomitant medications since both agents have a distinct toxicity profile, although they are generally well tolerated in the majority of patients. Expand
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
TLDR
Subcutaneous Campath-1H administered to CLL patients with residual BM disease after FAMP proved to be safe and effective, and three patients obtained a molecular CR and five converted into a morphologic and immunophenotypic CR. Expand
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
TLDR
Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features. Expand
...
1
2
3
4
5
...